Thomas Grissom

Reflecting his substantial public sector and corporate experience in health care policy, Thomas Grissom advises leading life sciences companies, including biomedical research, biotechnology, medical device, pharmaceutical, and information technology companies, on their federal regulatory and legislative concerns. He has special emphasis on matters before the United States Congress, Centers for Medicare and Medicaid Services (CMS), and the Food and Drug Administration (FDA). In his public policy advocacy, Thomas focuses on advising clients about a full range of Medicare and Medicaid issues. He uses his years of senior management experience in the CMS to shape policy and provide insight on Medicare and Medicaid coverage, reimbursement and payment, Medicare National Coverage Decisions, and reimbursement under the Hospital Outpatient and Inpatient Prospective Payment Systems. Thomas is active in Medicare Coverage Advisory Committee proceedings, as well as in the development of clinical and pharmacoeconomic data for both FDA product approval and CMS coverage and reimbursement. From 2001 until passage of the Medicare Modernization Act (MMA) in December 2003, Thomas served as Director of the CMS Center for Medicare Management. In that capacity he testified extensively to Congress on federal health policy, including before the House Energy and Commerce Committee and House Veterans’ Affairs Committee. He also directed the development and issuance of administrative rules affecting provider reimbursement and program operations for the Medicare fee-for-service program during the first administration of President George W. Bush. While at the CMS, Thomas initiated and co-chaired the CMS Council on Medical Technology, predecessor to the Council on Technology and Innovation. He also directed the CMS Contractor Reform Task Force that established a framework for provisions in the MMA.